Use of dual/tandem CAR constructs reduces relapse rate, with CD19/CD22 CAR-T therapy displaying efficacy in adult patients with B-cell lymphoma (Klampatsa, 2024). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.